We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Raising Suspicions with the Food and Drug Administration: Detecting Misconduct.
- Authors
Hamrell, Michael R.
- Abstract
The clinical Bioresearch Monitoring (BIMO) oversight program of the US Food and Drug Administration (FDA) assesses the quality and integrity of data submitted to the FDA for new product approvals and human subjects protection during clinical studies. A comprehensive program of on-site inspections and data verification, the BIMO program routinely performs random inspections to verify studies submitted to the FDA to support a marketing application. On occasion the FDA will conduct a directed inspection of a specific site or study to look for problems that may have previously been identified. The inspection of a clinical study sometimes uncovers evidence of research fraud or misconduct and it must be decided how to deal with the investigator and the suspect data. The prevention of [or] decreasing the incidence of fraud and misconduct through monitoring by the sponsor is one way to manage compliance issues and can help prevent misconduct. A training program is another way to manage compliance issues in clinical research. While training does not guarantee quality, it does help to ensure that all individuals involved understand the rules and the consequences of research misconduct.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; CLINICAL trials; MISCONDUCT in public office; FRAUD
- Publication
Science & Engineering Ethics, 2010, Vol 16, Issue 4, p697
- ISSN
1353-3452
- Publication type
Article
- DOI
10.1007/s11948-010-9232-4